Hubei Biocause Pharmaceutical (000627)

Shenzhen

Currency in CNY

1.66

-0.09(-5.14%)

Closed·08:44:59

Fair Value

Unlock Value

Day's Range

1.66

1.74

52 wk Range

1.64

5.42

000627 Income Statement

Featured here, the Income Statement (earnings report) for Hubei Biocause Pharmaceutical, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2022

01/01

2023

01/01

2023

31/12

Total Revenues

aa.aa

49,672.87

41,128.49

48,697.31

49,312.02

48,277.91

	Total Revenues Growth
	Premiums and Annuity Revenues
	Total Interest And Dividend Income
	Other Revenues

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+66.25%	-17.2%	+18.4%	+1.26%	-2.1%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	37,576.05	28,895.66	37,383.85	37,767.59	40,321.16
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	9,797.32	10,218.71	9,834.41	10,363.98	7,426.39
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,299.49	2,014.12	1,479.04	1,180.46	530.36

Total Operating Expenses

aa.aa

46,229.01

40,028.87

48,396.66

49,206.17

50,157.56

	Operating Expenses Growth
	Policy Benefits
	Policy Acquisition/Underwriting Costs, Total
	Other Operating Expenses, Total

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+69.72%	-13.41%	+20.9%	+1.67%	+1.93%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	37,096.92	36,140.02	40,290.49	40,949.64	40,160.55
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	3,542.68	2,381.88	3,410.47	3,061.07	3,131.48
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5,589.42	1,506.97	4,695.7	5,195.46	6,865.54

Operating Income

aa.aa

3,443.85

1,099.61

300.64

105.86

-1,879.65

Operating Income Growth

aa.aa

+30.45%

-68.07%

-72.66%

-64.79%

-1,875.67%

EBIT Margin %

aa.aa

6.93%

2.67%

0.62%

0.21%

-3.89%

Interest Expense, Total

aa.aa

Other Non Operating Expenses, Total

aa.aa

-22.19

-33.9

-15.2

72.02

20.47

EBT, Excl. Unusual Items

aa.aa

3,421.66

1,065.71

285.44

177.87

-1,859.18

EBT, Excl. Unusual Items Growth

aa.aa

+29.54%

-68.85%

-73.22%

-37.69%

-1,145.24%

Merger & Restructuring Charges

aa.aa

Gain (Loss) On Sale Of Assets

aa.aa

1.59

-0.31

-0.43

0.42

0.95

Other Unusual Items, Total

aa.aa

210.19

384.06

58.11

46.49

-9.77

EBT, Incl. Unusual Items

aa.aa

3,633.44

1,449.46

343.12

224.78

-1,868

EBT, Incl. Unusual Items Growth

aa.aa

+37.82%

-60.11%

-76.33%

-34.49%

-931.04%

Income Tax Expense

aa.aa

714.89

331.56

-537.09

-285.84

-586.5

Net Income to Company

aa.aa

2,918.55

1,117.91

880.22

510.62

-1,281.5

Minority Interest

aa.aa

-1,142.62

-537.61

-409.5

-236.57

629.74

Net Income

aa.aa

1,775.94

580.29

470.71

274.05

-651.76

Net Income Growth

aa.aa

+33.88%

-67.32%

-18.88%

-41.78%

-337.82%

Net Income Margin %

aa.aa

3.58%

1.41%

0.97%

0.56%

-1.35%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

1,775.94

580.29

470.71

274.05

-651.76

Basic EPS - Continuing Operations

aa.aa

0.36

0.12

0.1

0.06

-0.13

Basic EPS - Continuing Operations Growth

aa.aa

+33.33%

-66.67%

-16.67%

-40%

-316.67%

Diluted EPS - Continuing Operations

aa.aa

0.36

0.12

0.1

0.06

-0.13

Diluted EPS - Continuing Operations Growth

aa.aa

+33.33%

-66.67%

-16.67%

-40%

-316.67%

Basic Weighted Average Shares Outstanding

aa.aa

4,933.15

4,835.77

4,707.14

4,567.52

5,013.53

Diluted Weighted Average Shares Outstanding

aa.aa

4,933.15

4,835.77

4,707.14

4,567.52

5,013.53

Dividend Per Share

aa.aa

0.13

0.01

0.11

Dividend Per Share Growth

aa.aa

+333.33%

-92.31%

-50%

+2,100%

EBITDA

aa.aa

3,523.02

1,163.28

388.79

196.8

-1,778.41

EBITDA Growth

aa.aa

+28.92%

-66.98%

-66.58%

-49.38%

-1,003.68%

EBITDA Margin %

aa.aa

7.09%

2.83%

0.8%

0.4%

-3.68%

EBIT

aa.aa

3,443.85

1,099.61

300.64

105.86

-1,879.65

* In Millions of CNY (except for per share items)

NSE 30

4,931.77

+43.43

+0.89%

NSE All Share

134,424.23

+1,224.26

+0.92%

US 30

44,728.80

+34.7

+0.08%

US 500

6,372.30

+8.9

+0.14%

FTSE 100

9,104.78

-33.59

-0.37%

DAX

24,170.01

-137.01

-0.56%

South Africa Top 40

91,209.37

-1,048.91

-1.14%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	27.65	-2.98%	41.94M
Guaranty Trust Holding	94.00	-0.11%	28.00M
Zenith Bank	74.50	+1.78%	14.71M
MTN Nigeria	400.00	+1.27%	3.44M
Okomu Oil Palm	998.00	+5.05%	2.46M
Presco	1,550.00	+7.68%	900.61K
Seplat Petroleum	5,450.00	0.00%	337.85K

Name	Last	Chg. %	Vol.
Champion Brew	12.32	+10.00%	1.69M
Unilever Nigeria	68.20	+10.00%	1.19M
Ikeja	23.100	+10.00%	3.01M
Nigerian Enamelware PLC	25.00	+1.83%	110.03K
Initiates	16.13	+9.95%	3.53M
Academy Press	9.31	+9.92%	2.12M
Prestige	1.23	+9.82%	13.85M

Name	Last	Chg. %	Vol.
Transcorp Power	320.00	0.00%	89.84K
Abbey Mortgage Bank	7.20	-10.00%	260.32K
Geregu Power	1,027.40	-10.00%	994.00
Conoil	211.10	-9.98%	21.50K
Livingtrust Mortgage Bank	7.32	0.00%	37.88K
Sunu Assurances	4.48	-9.86%	18.34M
Aluminum Ex	6.45	-9.79%	4.20K

Trending Stocks

Name	Last	Chg. %	Vol.
Okomu Oil Palm	998.00	+5.05%	2.46M
Ellah Lakes	9.75	-2.50%	26.02M
Initiates	16.13	+9.95%	3.53M
Presco	1,470.00	+2.12%	884.37K
BUA Cement	127.00	-5.93%	908.85K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A Aaaa	5,450.00	+32.83%	7,239.23
Aaaaaaaaaa	66.50	+30.68%	86.90
Aaa A Aa	493.00	+24.69%	614.72
Aaaaaaaaaa Aa	135.00	+16.86%	157.76
Aaaaaa	400.00	+10.16%	440.64

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Hubei Biocause Pharmaceutical (000627)

000627 Income Statement

Trending Stocks